Advances in gastric cancer

Chair: Ian Chau
With Mitsuru Sasako, Kei Muro and Yung-Jue Bang

Saturday 17th December, 12:45-14:15
Hall 404, Suntec Singapore Convention and Exhibition Centre
## Contents

3  Learning objectives  
3  Programme  
4  Welcome message  
5  Faculty biographies: Ian Chau  
6  Faculty biographies: Mitsuru Sasako  
7  Faculty biographies: Kei Muro  
8  Faculty biographies: Yung-Jue Bang  
9  Symposium information  
10 Notes
Learning objectives

After attending this symposium, learners will be able to:

– Discuss the latest surgical and adjuvant treatments for gastric cancer according to patient and tumour characteristics, clinical guidelines and novel clinical data

– Assess the latest neoadjuvant and pre-surgery options for gastric cancer according to patient and tumour characteristics, clinical guidelines and novel clinical data in an Asian setting

– Describe the latest clinical trial data regarding translational research in metastatic gastric cancer therapy

– Evaluate best practice in the management of gastric cancer and how this best practice could be applied in their local healthcare setting

Programme

12:45 – 12:50 Welcome and introduction
Ian Chau
Royal Marsden Hospital, UK

12:50 – 13:20 The surgical treatment pathway
Mitsuru Sasako
Hyogo College of Medicine, Japan

Kei Muro
Aichi Cancer Center Hospital, Japan

13:45 – 14:10 Future directions in metastatic gastric cancer
Yung-Jue Bang
Seoul National University Hospital, South Korea

14:10 – 14:15 Summary and closing remarks
Ian Chau
Royal Marsden Hospital, UK
Dear Colleagues,

Welcome to Singapore and thank you for attending this independent satellite symposium entitled ‘Advances in gastric cancer’ at the ESMO Asia 2016 Congress.

The ESMO Asia 2016 Congress, with its aim to facilitate information exchange between Asian and European oncology professionals across continents, provides an ideal backdrop for this symposium where we hope to foster the sharing of experiences among those in the gastric cancer field.

The aim of this symposium is to discuss the latest surgical and oncology treatments for gastric cancer in the context of an increasingly complex treatment landscape including patient and tumour characteristics, clinical guidelines, and novel clinical data. We hope that by sharing the challenges facing clinicians both in Asia and Europe, our expert Faculty can help provide insights to aid the delegates in their clinical practice.

During this session, the expert Faculty will guide us through this complexity by placing the latest developments in gastric cancer in the context of treatment. They will then provide their insights into how we can best understand the latest developments in gastric cancer treatment in a multidisciplinary care team.

We hope that you find this symposium educational and that it will further your understanding of this evolving field. Accordingly, we aim to provide maximum interaction and discourse between Faculty and audience so that we may work together to optimise patient outcomes.

We would be grateful if you would kindly provide your feedback by completing the evaluation form provided with this booklet.

Yours faithfully,

Ian Chau – Chair
Faculty biographies

Ian Chau
(Symposium Chair)
Royal Marsden Hospital, UK

Dr Chau holds the position of Consultant Medical Oncologist within the Gastrointestinal and Lymphoma Units at the Royal Marsden Hospital and Honorary Senior Lecturer at the Institute of Cancer Research, London & Surrey. He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital.

His main research interests are clinical trials and translational research in gastrointestinal cancers and lymphoma. He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways.

Dr Chau serves or has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups. He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials.

Dr Chau has given invited lectures in over 30 countries, and has served on international drug development advisory boards. He has peer reviewed publications in *The New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology* and other leading oncology/biomedical journals.
Dr Sasako graduated from the Faculty of Medicine at Tokyo University in 1976 and later obtained his PhD from the same institution.

He spent one year as foreign assistant of the 5th University of Paris between 1984 and 1985 before moving to the National Cancer Center Hospital Tokyo in 1987. He was appointed as Boerhaave Professor of Leiden University in 1989. In 2007, he relocated as Professor of Surgery, Hyogo College of Medicine.

In 2016, he was appointed as Professor of the Department of Multidisciplinary Surgical Oncology of the same college.

Dr Sasako specialises in upper gastrointestinal oncology surgery. He has carried out numerous clinical trials on surgical and adjuvant treatment of gastric cancer, publishing more than 200 articles, which include 4 publications in the *The New England Journal of Medicine*.

Dr Sasako is committed to globally spreading Japanese concepts of oncological surgery and also Eastern clinical studies to international surgeons. He continues to establish standard treatment of gastric cancer not only in Japan but also in Europe and the USA.
Kei Muro
Aichi Cancer Center Hospital, Japan

Dr Muro graduated from the Faculty of Medicine, Tokyo in 1990 and completed his training of internal medicine at the Iwaki Kyoritsu Hospital in 1993. He then went on to complete his residency of Gastrointestinal Oncology Division at the National Cancer Center Hospital East in 1997 where he was also a Staff Doctor.

Later, in 2006, he became Chief of the Department of Clinical Oncology at Aichi Cancer Center Hospital, and adjunct Professor at Nagoya City University Graduate School of Medical Sciences a year later. In 2013, Dr Muro became adjunct Professor at Tokyo University Graduate School of Medical Science and also Director of the Outpatient Treatment Center at the Aichi Cancer Center.

Since 2015, Dr Muro has been Clinical Professor at the Nagoya City University Graduate School of Medical Sciences.
Yung-Jue Bang
Seoul National University Hospital, South Korea

Professor Bang, Professor of Medical Oncology, is the President of Biomedical Research Institute and Director of the Clinical Trials Center of Seoul National University Hospital.

He has been working for Seoul National University College of Medicine and Hospital since 1986. He has served many positions including Director of the Cancer Research Institute, Chairman of Department of Internal Medicine, and Chairman of the Korean Cancer Association.

Professor Bang has co-authored more than 400 papers in SCI-indexed journals including *The New England Journal of Medicine* and *The Lancet*. He is primarily interested in phase I trials and gastric cancer trials. He is the principal investigator of a number of international gastric cancer trials including ToGA, CLASSIC, SHINE, GOLD, and JAVELIN Gastric 300.
Symposium information

Organisers
This educational activity has been planned and independently implemented by Springer Healthcare IME. Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Nature publishing group.

Filming and photography
Springer Healthcare IME may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team of your objection to this, your consent will be implied.

Educational sponsorship
This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.